Literature DB >> 35618971

Expression of CD44 Isoforms in Tumor Samples and Cell Lines of Human Colorectal Cancer.

V O Novosad1, I S Polikanova2, E A Tonevitsky2, D V Maltseva2.   

Abstract

Detection of colorectal cancer biomarkers (CRC) remains an urgent task for the diagnosis and prediction of the disease course. A promising approach is the study of cancer stem cell markers. The cell surface glycoprotein CD44 is very important for CRC and its stem cells. Alternative splicing of 9 variable exons of CD44 mRNA leads to the formation of various isoforms of the protein with different roles in the progression of cancer. Studies of the functions of CD44 isoforms require adequate models considering the distribution of CD44 isoforms in real tumor samples. In the present study, the expression profile of CD44 isoforms in CRC was assessed based on the publicly available mRNA sequencing data of patient tumors from the TCGA-COAD database. It was shown that normal tissues predominantly expressed isoforms 3 and 4 at nearly equal levels, whereas tumors mainly expressed isoforms 2, 3, and 4; isoform 3 was expressed at the highest level. Further, the most relevant cell lines for studying the role of CD44 in CRC were identified based on the analysis of mRNA sequencing data of 55 CRC cell lines form CCLE database.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CCLE; CD44 isoforms; TCGA-COAD; colorectal cancer; mRNA sequencing

Mesh:

Substances:

Year:  2022        PMID: 35618971     DOI: 10.1007/s10517-022-05512-4

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  20 in total

1.  The prognostic value of CD44 expression in gastric cancer: a meta-analysis.

Authors:  Yansu Chen; Ziyi Fu; Sujuan Xu; Ye Xu; Pengfei Xu
Journal:  Biomed Pharmacother       Date:  2014-08-14       Impact factor: 6.529

Review 2.  Catalytic autoantibodies in clinical autoimmunity and modern medicine.

Authors:  Alexander G Gabibov; Natalya A Ponomarenko; Eugenia B Tretyak; Mikhail A Paltsev; Sergey V Suchkov
Journal:  Autoimmun Rev       Date:  2006-02-28       Impact factor: 9.754

3.  Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3.

Authors:  Andrew P Barbour; Jennifer A Reeder; Michael D Walsh; Jonathan Fawcett; Toni M Antalis; David C Gotley
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

4.  Targeting cancer stem cells: a new therapy to cure cancer patients.

Authors:  Yapeng Hu; Liwu Fu
Journal:  Am J Cancer Res       Date:  2012-04-28       Impact factor: 6.166

Review 5.  Importance of altered glycoprotein-bound N- and O-glycans for epithelial-to-mesenchymal transition and adhesion of cancer cells.

Authors:  Tobias Lange; Timur R Samatov; Alexander G Tonevitsky; Udo Schumacher
Journal:  Carbohydr Res       Date:  2014-01-15       Impact factor: 2.104

6.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome.

Authors:  Bo Li; Colin N Dewey
Journal:  BMC Bioinformatics       Date:  2011-08-04       Impact factor: 3.307

Review 7.  Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis.

Authors:  Jianqiang Chen; Jianding Zhou; Jie Lu; Hua Xiong; Xueli Shi; Liang Gong
Journal:  BMC Cancer       Date:  2014-01-13       Impact factor: 4.430

8.  The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis.

Authors:  Jiaying Lin; Ding Ding
Journal:  Cancer Cell Int       Date:  2017-01-05       Impact factor: 5.722

9.  CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications.

Authors:  Rita Azevedo; Cristiana Gaiteiro; Andreia Peixoto; Marta Relvas-Santos; Luís Lima; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Clin Proteomics       Date:  2018-06-27       Impact factor: 3.988

Review 10.  Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Xintao Li; Xin Ma; Luyao Chen; Liangyou Gu; Yu Zhang; Fan Zhang; Yun Ouyang; Yu Gao; Qingbo Huang; Xu Zhang
Journal:  Sci Rep       Date:  2015-08-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.